KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Retained Earnings (2016 - 2025)

Arbutus Biopharma's Retained Earnings history spans 15 years, with the latest figure at -$1.4 billion for Q3 2025.

  • For Q3 2025, Retained Earnings fell 3.17% year-over-year to -$1.4 billion; the TTM value through Sep 2025 reached -$1.4 billion, down 3.17%, while the annual FY2024 figure was -$1.3 billion, 5.48% down from the prior year.
  • Retained Earnings for Q3 2025 was -$1.4 billion at Arbutus Biopharma, down from -$48.2 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$48.2 million in Q1 2021 and bottomed at -$1.4 billion in Q3 2025.
  • The 5-year median for Retained Earnings is -$1.2 billion (2023), against an average of -$947.9 million.
  • The largest annual shift saw Retained Earnings plummeted 2628.99% in 2024 before it skyrocketed 96.33% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$48.3 million in 2021, then crashed by 2390.54% to -$1.2 billion in 2022, then dropped by 6.05% to -$1.3 billion in 2023, then decreased by 5.48% to -$1.3 billion in 2024, then dropped by 2.21% to -$1.4 billion in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Retained Earnings are -$1.4 billion (Q3 2025), -$48.2 million (Q2 2025), and -$1.4 billion (Q1 2025).